Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC by Francesca Lucibello, MD, Valérie Gounant, MD, PhD, Mihaela Aldea, MD, PhD, Michaël Duruisseaux, MD, PhD, Maurice Perol, MD, Christos Chouaid, MD, Jaafar Bennouna, MD, PhD, Vincent Fallet, MD, Aldo Renault, MD, Florian Guisier, MD, PhD, Etienne Giroux-Leprieur, MD, PhD, Marie Wislez, MD, PhD, Anne-Claire Toffart, MD, PhD, Julien Mazieres, MD, PhD, Clémence Basse, MD, PhD, Nadia Hegarat, PhD, Matthieu Carton, MD, Nicolas Girard, MD, PhD

Subjects: Get full text

Clinical audit of current Helicobacter pylori treatment outcomes in Singapore by Tiing Leong Ang, Kim Wei Lim, Daphne Ang, Yu Jun Wong, Malcolm Tan, Andrew Siang Yih Wong

Subjects: Get full text

RITUXIMAB VERSUS SPLENECTOMY IN CHRONIC PRIMARY ITP: EXPERIENCE OF A SINGLE HEMATOLOGY CLINIC by Rawanda Shamoon, Ahmed Khudair Yassin, Sarah Laith Alnuaimi

Subjects: Get full text

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second‐line monotherapy for patients with small‐cell lung cancer by Jieran Long, Xuefei Li, Lin Wu, Guohua Yu, Aimin Zang, Yanqiu Zhao, Jinsheng Shi, Ligong Nie, Xuan Zhao, Jian Fang

Subjects: Get full text

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab by Meng Wu, Claudia A.M. Fulgenzi, Antonio D’Alessio, Alessio Cortellini, Ciro Celsa, Giulia F. Manfredi, Bernardo Stefanini, Y. Linda Wu, Yi-Hsiang Huang, Anwaar Saeed, Angelo Pirozzi, Tiziana Pressiani, Lorenza Rimassa, Martin Schoenlein, Kornelius Schulze, Johann von Felden, Yehia Mohamed, Ahmed O. Kaseb, Arndt Vogel, Natascha Roehlen, Marianna Silletta, Naoshi Nishida, Masatoshi Kudo, Caterina Vivaldi, Lorenz Balcar, Bernhard Scheiner, Matthias Pinter, Amit G. Singal, Joshua Glover, Susanna Ulahannan, Fredrich Foerster, Arndt Weinmann, Peter R. Galle, Neehar D. Parikh, Wei-Fan Hsu, Alessandro Parisi, Hong Jae Chon, David J. Pinato, Celina Ang

Subjects: Get full text

Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan by S. Moe, I. Azamat, S. Allamuratova, M. Oluya, A. Khristusev, M.L. Rekart, K. Mamitova, G. Bidwell, C. Gomez-Restrepo, B. Kalmuratov, Z. Tigay, N. Parpieva, K. Safaev, N. Sitali, D. Gomez, A. Mikhail, A. Sinha

Subjects: Get full text

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression by Jianfeng Peng, Xueying Zhai, Xiaomei Liu, Zhaoqin Huang, Yimeng Wang, Peizhu Wu, Ran Gao, Xiangjiao Meng

Subjects: Get full text